What is Hypophosphatasia?
Hypophosphatasia (HPP) is a rare inherited disorder affecting bone and tooth mineralization caused by deficient activity of the enzyme alkaline phosphatase. The condition leads to soft, weak bones that are prone to fractures, along with dental problems and potential seizures in severe cases. HPP affects people of all ages, from infants to adults, with symptoms ranging from life-threatening complications in newborns to milder bone and dental issues in adults. Severe forms occur in approximately 1 in 100,000 births, making it one of the rarer bone diseases requiring specialized care and often presenting diagnostic challenges.
Key statistics
| Severe HPP prevalence | ~1 in 100,000 births |
| Mild HPP prevalence | ~1 in 6,370 (estimated) |
| Carrier frequency | ~1 in 300 for severe forms |
| Age of onset | Birth to adulthood (variable) |
Symptoms
Common symptoms: Low alkaline phosphatase levels, bone pain, dental problems, delayed walking, short stature, bone fractures, premature tooth loss, muscle weakness.
Severe infantile forms present with life-threatening complications including severe bone deformities, respiratory failure due to soft rib cage, seizures from low vitamin B6 levels, and failure to thrive. These infants may have shortened limbs, soft skull bones, and breathing difficulties.
Childhood forms typically manifest as delayed walking, waddling gait, bone pain, premature loss of primary teeth with roots intact, short stature, and increased susceptibility to fractures. Children may experience chronic pain and have difficulty with physical activities.
Adult forms often present with osteomalacia (soft bones), recurrent fractures especially of the feet and thighs, dental problems including early tooth loss, joint pain, and muscle weakness. Some adults may have chronic fatigue and experience stress fractures during normal activities.
Dental manifestations across all ages include premature tooth loss, delayed tooth eruption, enlarged pulp chambers, and increased susceptibility to dental caries and periodontal disease.
Causes and risk factors
Hypophosphatasia is caused by mutations in the ALPL gene, which provides instructions for making alkaline phosphatase enzyme. This enzyme is crucial for bone and tooth mineralization by breaking down compounds that inhibit mineral deposition.
The condition can be inherited in both autosomal recessive and autosomal dominant patterns. Severe forms are typically autosomal recessive, requiring two mutated gene copies, while milder adult forms often follow autosomal dominant inheritance, needing only one mutated copy.
Risk factors include having parents who are carriers of ALPL mutations, consanguineous marriages (marriages between relatives), and certain ethnic backgrounds where specific mutations may be more common. There are no known environmental risk factors that cause or worsen the condition.
Prevention
Hypophosphatasia cannot be prevented as it is a genetic condition present from birth. However, genetic counseling and testing can help families understand their risk of having affected children.
Genetic testing is available for individuals with family history or clinical suspicion of HPP. Carrier testing can identify individuals who carry one copy of a mutated gene, and prenatal testing is possible for pregnancies at risk.
Preconception counseling is recommended for couples with family history of HPP or known carrier status to discuss reproductive options including preimplantation genetic diagnosis.
Complications
Without appropriate treatment, severe HPP can lead to respiratory failure in infants due to chest deformities, developmental delays, chronic pain, and significantly reduced life expectancy.
Skeletal complications include progressive bone deformities, recurrent fractures, pseudofractures, and severe osteomalacia. Joint problems and arthritis may develop over time.
Dental complications can result in complete tooth loss, difficulty eating, and nutritional problems. Poor oral health can impact overall health and quality of life.
Neurological complications may include seizures due to vitamin B6 deficiency, particularly in severe infantile forms. Some patients experience chronic fatigue and muscle weakness that impacts daily functioning.
Diagnosis
Diagnosis of HPP relies on clinical features, biochemical testing, and genetic analysis. The diagnostic journey often involves multiple specialists and can take months or years due to the rarity of the condition.
Biochemical tests show characteristically low serum alkaline phosphatase levels, elevated phosphoethanolamine in urine, and increased pyridoxal 5′-phosphate (vitamin B6) in blood.
Imaging studies include X-rays showing osteomalacia, rickets-like changes, pseudofractures, and dental abnormalities. Bone density scans may reveal low bone mineral density.
Genetic testing confirms the diagnosis by identifying mutations in the ALPL gene. This testing also helps determine inheritance pattern and guides family counseling.
Dental examination may reveal enlarged pulp chambers, premature tooth loss, and delayed eruption patterns that support the diagnosis.
Treatment
Treatment has been revolutionized by the approval of asfotase alfa, an enzyme replacement therapy specifically developed for HPP. This orphan drug helps restore alkaline phosphatase activity and has shown significant benefits in severe forms of the disease.
Supportive care includes physical therapy to maintain mobility and prevent contractures, occupational therapy for daily living skills, and pain management strategies. Respiratory support may be necessary in severe infantile cases.
Orthopedic management involves careful fracture treatment, sometimes requiring specialized techniques due to poor bone healing. Joint replacement may be needed in severe cases.
Dental care requires specialized attention from dentists familiar with HPP, focusing on preventive care and appropriate treatment of dental complications.
Nutritional support ensures adequate calcium and vitamin D intake, though traditional osteoporosis medications are generally avoided as they may worsen the condition.
Prognosis
Prognosis varies dramatically based on the severity of the condition and age of onset. Severe infantile HPP historically had poor outcomes, with many infants not surviving their first year due to respiratory complications.
With asfotase alfa treatment, outcomes for severe forms have improved significantly, with better survival rates and quality of life. Children receiving early treatment show improved bone mineralization, growth, and development.
Milder forms generally have good long-term prognosis with appropriate management, though patients may experience chronic pain and mobility limitations. Life expectancy is typically normal in these cases.
Quality of life has improved substantially with better understanding of the condition and targeted therapies, though many patients still face ongoing challenges requiring comprehensive care.
Quality of life
Living with HPP requires adaptations to manage pain, prevent fractures, and maintain dental health. Regular exercise within individual limitations helps preserve bone and muscle strength, though high-impact activities should be avoided.
Diet and nutrition focus on adequate protein, calcium, and vitamin D intake to support overall bone health. Working with a dietitian familiar with metabolic bone diseases is beneficial.
Mental health support is important given the chronic nature of the condition and its impact on daily activities. Support groups and counseling can help patients and families cope with the challenges.
Work and school accommodations may be necessary to manage fatigue, pain, and mobility limitations. Many patients lead productive lives with appropriate support and understanding from employers and educators.
Pregnancy and fertility
HPP does not typically affect fertility, but pregnancy requires careful monitoring due to potential complications. Women with HPP may experience increased bone pain and fracture risk during pregnancy and breastfeeding.
Genetic counseling is essential for family planning, as there is a risk of passing the condition to children. The risk depends on the inheritance pattern and partner’s carrier status.
Medication safety during pregnancy requires discussion with healthcare providers, particularly regarding asfotase alfa use, though limited data suggests it may be safe during pregnancy.
Children
Children with HPP require multidisciplinary care including pediatric endocrinology, orthopedics, dentistry, and physical therapy. Early intervention is crucial for optimal outcomes.
School considerations include physical activity modifications, potential mobility aids, and understanding from teachers about the child’s limitations and needs.
Growth monitoring is important as many children have short stature and delayed development. Nutritional support and physical therapy help optimize growth potential.
Dental care should begin early with pediatric dentists experienced in metabolic bone diseases to prevent and manage dental complications.
When to see a doctor
Emergency care is needed for severe bone pain, suspected fractures, breathing difficulties, or seizures, particularly in children with known or suspected HPP.
Routine care should be sought for delayed tooth eruption, premature tooth loss, unexplained bone pain, frequent fractures, or delayed motor development in children.
Specialist referral is appropriate when HPP is suspected based on clinical features, family history, or unexplained low alkaline phosphatase levels.
Regional context
Specific prevalence data for hypophosphatasia in the Caucasus region (Georgia, Armenia, Azerbaijan) and Eastern Mediterranean is limited. However, consanguineous marriages more common in some populations may increase the risk of autosomal recessive forms. Healthcare providers in these regions who encounter patients with unexplained bone disease, dental problems, or low alkaline phosphatase levels are encouraged to consider HPP in their differential diagnosis. The Global Medical Journal welcomes contributions from regional specialists to better understand the local epidemiology and clinical presentation of this rare condition.
Research and clinical trials
Current research focuses on improving enzyme replacement therapy, developing new treatment approaches, and better understanding the natural history of HPP. Studies are investigating optimal dosing strategies for asfotase alfa and its long-term effects.
Gene therapy approaches are being explored as potential future treatments, offering hope for more targeted and effective interventions.
Biomarker research aims to develop better ways to monitor disease progression and treatment response.
Patients and families can find information about ongoing clinical trials at ClinicalTrials.gov using the search term “hypophosphatasia.” Participation in research studies helps advance understanding and treatment of this rare condition.
Frequently asked questions
Is hypophosphatasia the same as osteoporosis?
No, while both conditions affect bones, HPP is a genetic enzyme deficiency causing mineralization problems, whereas osteoporosis involves bone density loss. HPP patients should not receive typical osteoporosis medications as they may worsen the condition.
Can hypophosphatasia be cured?
Currently, there is no cure for HPP, but asfotase alfa provides effective enzyme replacement therapy that can significantly improve symptoms and outcomes, especially when started early.
Will my child inherit hypophosphatasia if I have it?
The inheritance risk depends on the type of HPP and your partner’s genetic status. Genetic counseling can provide specific risk estimates based on your situation and help guide family planning decisions.
Why do people with HPP lose teeth early?
HPP affects the formation of cementum, the tissue that anchors teeth to the jawbone. Without proper cementum formation, teeth become loose and fall out prematurely, often with their roots intact.
Can adults develop hypophosphatasia later in life?
HPP is present from birth, but mild forms may not be diagnosed until adulthood when symptoms like stress fractures, dental problems, or joint pain become apparent. The genetic mutation is present throughout life.
Support and resources
Patient organizations:
– Soft Bones Foundation: https://www.softbones.org
– NORD (National Organization for Rare Disorders): https://rarediseases.org
– EURORDIS (European Organisation for Rare Diseases): https://www.eurordis.org
– Orphanet: https://www.orpha.net
Medical resources:
– GeneReviews HPP: https://www.ncbi.nlm.nih.gov/books/NBK83705/
– OMIM Hypophosphatasia: https://omim.org/entry/241500
Related conditions
– Osteogenesis imperfecta
– Rickets
– Osteomalacia
– X-linked hypophosphatemia
– Fibrous dysplasia
Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, relevant guidelines. Informational only; not medical advice. CC BY 4.0.
Cite this page
GMJ News Desk. “Hypophosphatasia.” GMJ News — Georgian Medical Journal, 2 June 2026. https://news.gmj.ge/condition/hypophosphatasia/
Licensed under CC BY 4.0. Free to share with attribution to GMJ News.Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, EULAR/ACR guidelines. Schema.org MedicalCondition structured data included.
Was this article helpful?